Given its mode of action as a binder to a ubiquitously expressed surface receptor, one would expect Polatuzumab to be less subgroup-selective than targeted therapeutics, and hence to exert its activity across all DLBCL patients—among them, many not in need of more than R-CHOP. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.